Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Akeega Approval Means Three-Way PARP/Anti-Androgen Race In Prostate Cancer Is On

Aug 14 2023

• By Alaric DeArment

J&J's Akeega won FDA approval on 11 August • Source: Shutterstock

Related Content

AstraZeneca’s Lynparza Adds Narrow Prostate Cancer Indication

Jun 01 2023

Pfizer Scores Broad Label For Talzenna/Xtandi In Valuable First-Line Prostate Cancer Indication

Jun 21 2023

Narrow Label Will Restrict J&J’s Akeega In Prostate Cancer Combination Battle

Apr 25 2023

Data PROpel Lynparza To Potential Prostate Cancer Megablockbuster

Sep 24 2021

J&J Wins EU Nod For Akeega To Go Up Against AZ/MSD’s Lynparza In First-Line mCRPC

Feb 28 2023

Related Companies

Johnson & Johnson

Janssen Pharmaceutical Cos.

AstraZeneca PLC

Merck & Co., Inc.

Pfizer Inc.

GSK plc

Astellas Pharma, Inc.

Additional Topics

Approvals Commercial Cancer BioPharmaceutical

More from New Products

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window